Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop Report.

{"article_title":"Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop Report.","author":"Shubow, Sophie , Gunsior, Michele , Rosenberg, Amy , Wang, Yow-Ming , Altepeter, Tara , Guinn, Daphne , Rajabiabhari, Mohsen , Kotarek, Joseph , Mould, Diane R , Zhou, Honghui , Cheifetz, Adam S , Garces, Sandra , Chevalier, Rachel , Gavan, Sean , Trusheim, Mark R , Rispens, Theo , Bray, Kurtis , Partridge, Michael A","journal_title":"The AAPS journal","issn":"1550-7416 ; Electronic","isbn":"","publication_date":"20250314","volume":"27","issue":"2","first_page":"62","page_count":"","accession_number":"40087239","doi":"10.1208\/s12248-025-01050-9","publisher":"American Association of Pharmaceutical Scientists","doctype":"Journal Article; Research Support","subjects":"Pharmacology ","interest_area":["Internal\/Family Medicine"],"abstract":"Declarations. Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official views of the FDA. Conflict of Interest: ASC has received consulting fees from Abbvie, Aegirbio (SAB), Artizan (SAB), Prometheus (SAB), Fzata, Adiso, BMS, Clario, Food is Good, Fresenius Kabi, Janssen, Lilly, Pfizer, Procise, Spherix, Samsung; and speaking fees (non-branded) from Abbvie, BMS, Janssen. MRT has received consulting fees from Boehringer Ingelheim, Janssen Pharmaceuticals, Merck, Pfizer, Roche Pharmaceuticals, UniQure. DRM is president of Projections Research Inc, a consulting company working with the pharmaceutical industry. The remaining authors report no conflict of interest.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=40087239&authtype=shib&custid=ns346513"}